Quoin Pharmaceuticals - Aggregate net proceeds expected to fund Quoin into second half of 2029

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has made significant regulatory and clinical progress in 2026, advancing its lead candidate, QRX003, for the treatment of Netherton Syndrome. The company has secured multiple designations across key markets, including Fast Track Designation from the U.S. FDA, Orphan Drug Designation in Japan, and Breakthrough Medicine Designation applications in Saudi Arabia. These regulatory milestones are expected to streamline the development and approval process for QRX003, potentially positioning it as first approved treatment for Netherton.

In the first quarter of 2026, Quoin reported continued enrollment in its Phase 3 clinical trial for QRX003, with recruitment on track to be completed by the end of 2026. The company also announced plans to file a New Drug Application (NDA) in 2027. Additionally, Quoin is expanding its pipeline through its QRX009 topical rapamycin platform, with investigator-led studies planned for conditions such as Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.

Financially, as of March 31, 2026, Quoin held approximately $14 million in cash, cash equivalents, and marketable securities. The company reported a net loss of $5 million for the quarter, compared to $3.8 million in the same period in 2025. Quoin believes current cash position will fund operations into 2027. With recent capital raises and ongoing regulatory support, including the extension of the Rare Pediatric Disease Priority Review Voucher Program through 2029, Quoin is positioned to advance its development programs and potentially achieve key commercial milestones.